MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Bruker Corporation Cost of Revenue 2011-2026 | BRKR
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Bruker Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.72 B | 1.45 B | 1.22 B | 1.21 B | 1.05 B | 1.08 B | 996 M | 950 M | 866 M | 915 M | 1.05 B | 1.03 B | 962 M | 899 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.72 B | 866 M | 1.1 B |
Quarterly Cost of Revenue Bruker Corporation
| 2025-Q3 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 481 M | 410 M | - | 446 M | 416 M | 369 M | - | 360 M | 341 M | 326 M | - | 304 M | 290 M | 289 M | - | 300 M | 290 M | 276 M | - | 263 M | 238 M | 232 M | - | 267 M | 260 M | 247 M | - | 244 M | 238 M | 232 M | - | 237 M | 230 M | 208 M | - | 209 M | 202 M | 209 M | - | 229 M | 227 M | 193 M | - | 252 M | 257 M | 244 M | - | 246 M | 253 M | 219 M | - | 238 M | 232 M | 215 M | - | 229 M | 218 M | 195 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 481 M | 193 M | 270 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M |  USA |
 |
Insulet Corporation
PODD
|
768 M | $ 216.0 | -4.21 % | $ 15.2 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Profound Medical Corp.
PROF
|
3.92 M | $ 5.82 | 13.01 % | $ 180 M |  Canada |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Quanterix Corporation
QTRX
|
73.9 M | $ 3.96 | 3.66 % | $ 169 M | USA |
 |
AVITA Medical
RCEL
|
12.8 M | $ 3.99 | 3.91 % | $ 111 M |  Australia |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.33 | -1.85 % | $ 21.5 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
IRadimed Corporation
IRMD
|
19.5 M | $ 101.78 | 0.8 % | $ 1.29 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Sintx Technologies
SINT
|
557 K | $ 2.56 | -0.39 % | $ 7.1 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 37.08 | 1.42 % | $ 1.15 B | USA |
 |
Smith & Nephew plc
SNN
|
1.54 B | - | - | $ 23.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
15.6 M | $ 4.22 | 6.57 % | $ 68.9 M | USA |
 |
NanoVibronix
NAOV
|
1.05 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
14 M | $ 24.66 | -0.16 % | $ 208 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M | Canada |
 |
Tactile Systems Technology
TCMD
|
79.4 M | $ 26.96 | 0.37 % | $ 617 M | USA |
 |
TELA Bio
TELA
|
18 M | $ 0.69 | -9.35 % | $ 15.8 M | USA |
 |
Tandem Diabetes Care
TNDM
|
469 M | $ 24.26 | -1.02 % | $ 1.65 B | USA |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.67 | -3.52 % | $ 36.5 M | USA |
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.32 | 7.41 % | $ 3.62 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
InspireMD
NSPR
|
6.33 M | $ 1.77 | -1.12 % | $ 114 M |  Israel |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 11.39 | -0.78 % | $ 1.54 B | USA |
 |
Penumbra
PEN
|
461 M | $ 336.27 | 0.63 % | $ 13.1 B | USA |
 |
Myomo
MYO
|
14 M | $ 0.7 | -0.1 % | $ 29.3 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
21.9 M | $ 2.29 | -4.58 % | $ 134 M | Israel |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.71 | -5.12 % | $ 138 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 16.23 | 2.01 % | $ 381 M | USA |
 |
Outset Medical
OM
|
72.7 M | $ 3.53 | - | $ 53.7 K | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 51.41 | -1.27 % | $ 1.51 B | USA |
 |
Varex Imaging Corporation
VREX
|
554 M | $ 10.69 | 0.66 % | $ 443 M | USA |